News

Lucía Enríquez at Kyoto University: Advancing Cystic Fibrosis Research Through iPS Technology

Lucía Enríquez shares her research stay at Kyoto University, advancing cystic fibrosis models with iPS cells and NANBIOSIS Unit 10 technologies.

Kyoto, February 2026 — International research stays are key to accelerating innovation in biomedicine. Lucía Enríquez, a PhD researcher linked to NANBIOSIS Unit 10, is currently carrying out a research stay at Kyoto University, one of the world’s leading institutions in stem cell research. In this interview, she shares how this experience is helping bridge advanced induced pluripotent stem cell (iPS) technology, non-viral gene delivery systems, and 3D bioprinting to improve disease modeling for cystic fibrosis.

Below is the full interview transcript. See the video at the end of this article.

Interview with Lucía Enríquez

Q: Lucía, you are currently carrying out a research stay in Kyoto. Where are you working, and why is this center considered a world leader in its field?

Answer:
Right now, I’m working at Kyoto University. I’m doing an international research stay during my PhD in Spain, which is focused on studying cystic fibrosis as a pathology. What we’re doing here are models of the disease that are more representative of the patient’s genetic profile.

For this purpose, we’re using iPS cells, which are cells derived from patients that are reprogrammed to be pluripotent. iPS stands for Induced Pluripotent Stem cells. What we do is obtain cells from a patient, reprogram them to be pluripotent, and then differentiate them into the tissue that we want to study. In this case, since cystic fibrosis has a strong impact on the pulmonary system, we develop them into airway epithelium.

The reason why this center is a leader in the field is because it was founded by Shinya Yamanaka, who received the Nobel Prize in Physiology or Medicine in 2012. He discovered the reprogramming factors that allow a fully differentiated cell to be transformed back into a pluripotent state — an induced pluripotent stem cell.

Q: This technology seems very useful in personalized medicine. Cystic fibrosis is considered a rare disease, correct?

Answer:
Yes, cystic fibrosis is one of the least rare among rare diseases, but it is still considered a rare disease. And yes, iPS technology helps you model genetic pathologies very effectively.

Studying human genetic diseases is complex because traditional in vitro cellular models usually involve only one cell type. That does not reflect physiological reality. With iPS cells, you can generate multicellular structures in vitro derived from the same patient, meaning they are genetically homogeneous. This allows you to better understand what is happening and how cells respond, in a more physiologically relevant environment — without relying directly on human or animal models.

Q: You obtained a JSPS fellowship, which is highly competitive. What did this opportunity mean to you?

Answer:
The JSPS is the Japan Society for the Promotion of Science, which offers several grants. I was awarded a short-term postdoctoral fellowship. It is primarily intended for international postdoctoral researchers, but it can exceptionally be awarded to final-year PhD students with strong projects.

They award 25 grants per call worldwide, so it is highly competitive. I was fortunate to be one of the non-postdoctoral exceptions.

Professionally and personally, it has been a great experience. Moving from Spain to Japan and immersing myself in a different research and cultural environment has been enriching. Importantly, this grant included research funding — the first time I have had dedicated funding to manage myself. This allowed me to attend a Keystone symposium in Kyoto in January, which would not have been possible otherwise.

Q: How does this research connect with your PhD work at NANBIOSIS Unit 10?

Answer:
At NANBIOSIS Unit 10, we have two main lines of work:

1. The synthesis, optimization, production, and characterization of non-viral vectors for gene delivery and other delivery systems.
2. 3D bioprinting and characterization of human tissues, mainly for regenerative medicine and disease modeling.

The idea was to combine these technologies: iPS cell technology from Kyoto, non-viral gene delivery systems, and 3D bioprinted airway epithelia modeling cystic fibrosis tissue.

We aim to develop non-viral vectors to transfect or treat iPS cells and use them to generate 3D bioprinted models of cystic fibrosis airway epithelium.

Q: What new approaches have you found in this laboratory compared to Spain?

Answer:
I have not found dramatic differences in research workflows, which is actually reassuring.

I came here specifically to learn about iPS technology and differentiation into pulmonary lineage cells. These cells behave differently from immortalized cell lines. They are more sensitive and require different characterization approaches.

I have learned new workflows that complement my previous experience in Spain. The goal is to merge this new knowledge with what we do at home and strengthen collaborative approaches.

Q: How would you describe the capabilities and international position of NANBIOSIS Unit 10?

Answer:
In science, you rely on experts with different skill sets. Good research centers have strong infrastructures and specialized technical staff.

NANBIOSIS is a platform that allows researchers to expand their ideas beyond a single center, at a national level. It is a very unique infrastructure. Here in Japan, services are often internal to each research center. There is less of a nationwide shared infrastructure model.

With NANBIOSIS, researchers can access a wide range of expertise across Spain. I believe this is something we should value and promote internationally.

Q: What can you contribute to the Kyoto laboratory?

Answer:
iPS cells are widely used for tissue regeneration and disease modeling.

In regenerative applications, lipid-based non-viral vectors can genetically modify cells before transplantation, increasing therapeutic potential in a safer way.

In disease modeling, these vectors can be optimized in vitro before moving to in vivo studies. These technologies are highly complementary and work very well together.

Q: Has living and working in Kyoto influenced your scientific perspective?

Answer:
Yes. I’m in the final year of my PhD, and this is when you start reflecting on your future.

Being here has broadened my perspective — professionally and personally. It has shown me that opportunities can arise anywhere. In my opinion, very few things are truly impossible. Keep your doors open and work towards what you want.

Q: What advice would you give to young researchers considering international fellowships?

Answer:
If you’re a researcher, you’re probably curious by nature — embrace that curiosity.

Be persistent. Talk to people. You will receive many “no’s,” but that is part of research and life. Don’t be afraid to reach out.

Some people told me not to apply for this grant because it was too competitive. My answer was simple: maybe I won’t get it, but it won’t be because I didn’t try.

Just try. Keep working on what interests you.

Strengthening International Collaboration in Nanomedicine

Lucía Enríquez’s research stay exemplifies how international mobility enhances scientific innovation. By combining iPS cell technology from Kyoto with non-viral gene delivery systems and 3D bioprinting expertise from NANBIOSIS Unit 10, this collaboration advances personalized disease modeling for cystic fibrosis and strengthens Spain–Japan scientific ties.

Such synergies reflect the mission of NANBIOSIS: providing cutting-edge biomedical research infrastructures that empower researchers to push the boundaries of nanomedicine, gene delivery, and regenerative medicine.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

NANBIOSIS researchers contribute to the 2nd CSIC Rare Diseases Network Meeting in Madrid

NANBIOSIS researchers join the 2nd CSIC Rare Diseases Network Meeting in Madrid, strengthening interdisciplinary collaboration in rare disease research.

Madrid, February 2026 — Several researchers from NANBIOSIS and CIBER-BBN based at the IQAC-CSIC took part in the 2nd Meeting of the CSIC Rare Diseases Network, held in Madrid. The event brought together scientists, legal experts, patients, sociologists, and other key stakeholders to address rare diseases from a truly interdisciplinary perspective.

Among the participants were Miriam Royo, Scientific Director of Unit 3, Lluïsa Villaplana, researcher from Unit 2 and Ibane Abasolo, Strategy Advisor of NANBIOSIS. Their participation highlights the strong commitment within NANBIOSIS towards collaborative biomedical research and to advancing knowledge in rare diseases through cutting-edge infrastructures.

Interdisciplinary collaboration for Rare Diseases

Rare diseases affect millions of people worldwide, yet many remain underdiagnosed and lack effective treatments. The CSIC Rare Diseases Network meeting provided an enriching forum to exchange experiences not only among researchers, but also with professionals from the legal and social sciences, as well as patient representatives.

This multidisciplinary dialogue is essential to address the scientific, regulatory, and societal challenges associated with rare disease research, from biomarker discovery to preclinical validation and translational development.

NANBIOSIS Units supporting Rare Disease research

The participation of NANBIOSIS researchers reflects the strategic role of its Units in supporting high-impact biomedical research

Unit 3 – Synthesis of Peptides Unit

Unit 3, coordinated by the Multivalent Systems for Nanomedicine group at IQAC-CSIC, offers advanced services in peptide synthesis (from milligrams to grams), purification, characterization, and post-synthesis modifications, including conjugation to proteins and fluorescent labels.

With extensive expertise in biologically active peptide design and in their incorporation into therapeutic nanoconjugates, Unit 3 supports the development of innovative strategies for targeted therapies—an essential area for many rare diseases with limited treatment options.

Unit 2 – Custom Antibody Service (CAbS)

Unit 2 at IQAC-CSIC is equipped for the development and production of monoclonal and polyclonal antibodies, including hybridoma generation, antibody purification, immunoassays, and bioconjugate synthesis. The Unit operates under ISO9001 certification, ensuring standardized quality control procedures.

Its capabilities in antibody production and immunoreagent development are highly relevant for rare disease research, particularly in biomarker validation, diagnostic assay development, and targeted therapeutic approaches.

By participating in the 2nd CSIC Rare Diseases Network Meeting, NANBIOSIS researchers reinforce the infrastructure’s role as a key enabler of collaborative, translational, and interdisciplinary research in rare diseases—helping bridge the gap between fundamental science and clinical application.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

How a tumor metabolite changes Glioma behavior and improves treatment response

A new study shows how a tumor metabolite can make aggressive glioma cells more sensitive to treatment, revealing new opportunities for therapy.

Valencia, February 2026 — A recent study published in Biomedicines shows that D-2-hydroxyglutarate (2HG), a molecule produced by certain brain tumors, can significantly change how glioma cells behave. The research demonstrates that when IDH-wildtype glioma cells are exposed to 2HG, they begin to resemble IDH-mutant tumors, becoming less aggressive and more sensitive to standard cancer treatments. The study involved the use of NANBIOSIS research infrastructure (more specifically, Unit 26), underlining its role in advanced biomedical research.

The article, titled “Isocitrate Dehydrogenase-Wildtype Glioma Adapts Toward Mutant Phenotypes and Enhanced Therapy Sensitivity Under D-2-Hydroxyglutarate Exposure” (Biomedicines, 2025), explores how tumor metabolism influences the growth, spread, and treatment response of gliomas.

What are IDH mutations and why do they matter?

Some gliomas carry mutations in a gene called isocitrate dehydrogenase (IDH). These mutations cause tumor cells to produce 2HG, a so-called “oncometabolite” that alters how cells grow and function. Interestingly, patients with IDH-mutant gliomas often respond better to treatment, but the reasons behind this have not been fully understood.

To better understand this effect, researchers compared glioma cells with and without IDH mutations. They studied how the cells behaved under low-oxygen conditions, which are common inside tumors, and how they responded to chemotherapy (temozolomide) and radiotherapy.

What did the researchers find?

The study (full reference at the end of this piece) found clear differences between the two types of tumor cells:

• IDH-wildtype glioma cells grew faster and adapted more easily to low oxygen levels
• IDH-mutant cells divided more slowly and showed signs of growth arrest

When IDH-wildtype cells were exposed to 2HG, however, they began to change. These cells showed slower growth, increased cell death during chemotherapy, and changes in surface markers linked to tumor aggressiveness. In other words, 2HG made aggressive tumor cells behave more like the less aggressive IDH-mutant tumors.

Evidence from animal models

The researchers also tested these effects in mouse models of glioma. Tumors formed from IDH-wildtype cells were larger and spread more into surrounding brain tissue. In contrast, tumors exposed to 2HG were smaller and more compact.

Although some tumor cells became more mobile over time, this movement was strongly reduced when chemotherapy or radiotherapy was applied. This suggests that 2HG exposure may increase the effectiveness of existing treatments.

These findings show that tumor metabolism plays a key role in how gliomas grow and respond to therapy. While IDH mutations and 2HG may initially help tumor cells survive, they also appear to make tumors more vulnerable to treatment and less invasive.

Understanding this balance could help researchers identify new treatment strategies that exploit these weaknesses, potentially improving outcomes for patients with glioblastoma and other gliomas.

NANBIOSIS infrastructure supporting the study

This research involved the use of NANBIOSIS Unit 26 (U26. NMR: Biomedical Applications II). The BMRI-3T (MR Solutions) system, registered at the Unit 26 facility of ICTS NANBIOSIS at the Universitat de València, was used for in vivo imaging studies. The authors also acknowledged Musta Ezzedin Ayoub from the UCIM–Universitat de València imaging team for his contribution to image acquisition.

NANBIOSIS Unit 26 is based at the Faculty of Medicine of the University of Valencia and provides advanced NMR and imaging technologies for biomedical research. The Unit supports studies on metabolism, disease mechanisms, and treatment response in both academic and industrial projects.

Read the full paper here.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

NANBIOSIS advances targeted nanomedicine for Acute Myeloid Leukemia on World Cancer Day

NANBIOSIS Unit 18 contributes to two studies advancing CXCR4-targeted nanoconjugates for acute myeloid leukemia, highlighted on World Cancer Day.

On the occasion of World Cancer Day, NANBIOSIS highlights the recent publication of two scientific articles advancing a novel line of research focused on the development of targeted nanoconjugates for the treatment of acute myeloid leukemia (AML). Both studies include the active participation of NANBIOSIS Unit 18, reinforcing the Unit’s role in the preclinical development and evaluation of innovative cancer nanomedicines.

Optimizing conjugation strategies to enhance antitumor efficacy

The first study, “Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates”, addresses a key challenge in cancer nanomedicine: improving therapeutic selectivity while minimizing systemic toxicity. While antibody–drug conjugates (ADCs) are considered the gold standard in targeted therapies, their clinical limitations have driven the search for alternative approaches.

In this work, researchers evaluated how site-specific conjugation strategies influence the biodistribution and antitumor efficacy of a CXCR4-targeted multivalent protein nanocarrier loaded with the cytotoxic drug monomethyl auristatin E (MMAE). The results demonstrated that precise payload positioning significantly impacts therapeutic performance. Notably, a site-specific design achieved comparable tumor control with a four-fold lower drug load, highlighting the potential of dose-sparing strategies in next-generation protein-based nanomedicines.

Precision targeting of CXCR4⁺ leukemia cells in AML models

The second publication, “Precision targeting of CXCR4+ leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model”, focuses on overcoming chemoresistance and relapse in AML, which are largely driven by therapy-resistant leukemic stem cells in the bone marrow.

The study describes the development of T22-HSNBT-H6-MMAE, a humanized nanoconjugate designed to selectively target CXCR4-overexpressing leukemia cells, a biomarker associated with poor prognosis in approximately 50% of AML patients. In vitro and in vivo experiments demonstrated potent antileukemic activity, including complete suppression of leukemic dissemination and prolonged survival in a disseminated AML mouse model, without systemic toxicity. Importantly, the nanoconjugate showed selectivity for malignant cells while sparing healthy bone marrow and peripheral blood cells.

The role of NANBIOSIS Unit 18

NANBIOSIS Unit 18, located at the Hospital de la Santa Creu i Sant Pau (Barcelona) and coordinated by Dr. Ramón Mangues, specializes in nanotoxicology and preclinical safety assessment. The Unit evaluates the toxicity and tolerability of new drugs, nanoparticles and nanotechnology-based biomaterials using in vitro and in vivo models, supporting the optimization of lead compounds with higher probabilities of clinical success.

With advanced facilities for cell culture, flow cytometry, confocal microscopy and in vivo experimentation in small animal models, Unit 18 plays a key role in ensuring the safety, efficacy and translational potential of innovative nanomedicine approaches.

Together, these two studies underscore the contribution of NANBIOSIS to cutting-edge cancer research and highlight the promise of CXCR4-targeted nanoconjugates as a new therapeutic strategy for patients with acute myeloid leukemia.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

NANBIOSIS Unit 2 (CAbS) at the III SENTIATECH Meeting on Science, Technology & Health Risk Monitoring

NANBIOSIS Unit 2 (CAbS) participates in the III SENTIATECH Meeting, showcasing nanobiotechnology and diagnostics for health risk monitoring.

NANBIOSIS is actively represented at the III SENTIATECH Meeting | Science, Technology & Health Risk Monitoring through the Nb4D research group, in which NANBIOSIS Unit 2 “CAbS” is integrated. This third edition of the SENTIATECH Meeting focuses on presenting the SENTIATECH platform and strengthening collaboration between research centers and industry to tackle current and emerging challenges in defense and chemical–biological risk management.

During the meeting, Dr. J. Pablo Salvador, Tenured Scientist and member of the Nb4D group, is coordinating Working Group 4 (WG4), dedicated to the monitoring and diagnosis of health-related risks. This working group addresses key scientific and technological strategies for early detection, surveillance, and response to threats affecting human health.

In parallel, the Nb4D group has a dedicated exhibition space at the event, where it is presenting its research and technological capabilities in nanobiotechnology, diagnostics, and antibody-based solutions. As experts in immunoassay development, the group showcases advanced tools for the detection of pathogens, toxins, chemical contaminants, and other threatening substances, reinforcing the relevance of NANBIOSIS infrastructures in high-impact risk scenarios.

The SENTIATECH Meeting brings together stakeholders from academia, research institutions, and industry with the shared objective of:

• Presenting technological solutions for defense and chemical–biological risk scenarios
• Fostering collaborative synergies between science and industry
• Defining a strategic agenda to address emerging and future risks effectively

Participation in this forum highlights the commitment of NANBIOSIS and its units to technology transfer, innovation, and the application of cutting-edge science to protect human health and security.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Open Call page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Preclinical Histology Workflow within NANBIOSIS

New video shows the Preclinical Histology workflow of NANBIOSIS Unit 20 at VHIR, part of an integrated platform for preclinical validation and imaging.

NANBIOSIS has published a new video on its YouTube channel showcasing the Preclinical Histology Section, one of the key service areas of NANBIOSIS Unit 20 – In vivo Experimental Platform, located at the Vall d’Hebron Research Institute (VHIR) in Barcelona.

The Preclinical Histology Section provides specialized tissue processing and staining services for the evaluation of therapeutic compounds and biomarkers in preclinical research. Operating within ISO-certified facilities, the team works with both paraffin-embedded and OCT-embedded frozen samples, offering high-level expertise in histological staining, immunohistochemistry, and immunofluorescence.

The video focuses on the paraffin-embedded sample workflow, demonstrating each step of the process: reception and classification of formalin-fixed samples, automated tissue processing, paraffin embedding, precise block orientation, microtome sectioning, and hematoxylin–eosin staining. The section routinely handles a wide range of biological materials, from whole organs to delicate tissues and advanced 3D models such as organoids, ensuring reproducibility and high-quality results.

Importantly, the Preclinical Histology Section is part of the broader NANBIOSIS Unit 20, which comprises three integrated sections: Molecular Imaging, Preclinical Animal Models, and Preclinical Histology. All three are embedded within the Functional Validation & Preclinical Research (FVPR) area of CIBBIM-Nanomedicine. This integrated structure enables Unit 20 to offer comprehensive preclinical proof-of-concept validation services.

Led by Dr. Ibane Abasolo, Head of FVPR, Unit 20 stands out for combining toxicology, histopathology, and efficacy studies with non-invasive optical imaging technologies, including in vivo bioluminescence and fluorescence imaging. This unique combination allows longitudinal monitoring of living animal models, providing real-time insights into treatment efficacy, biodistribution, and mechanisms of action. While similar imaging technologies exist elsewhere in Spain, Unit 20 is unique in offering them fully integrated with dedicated preclinical animal models.

This new video offers a practical glimpse into the high-quality preclinical services available through NANBIOSIS Unit 20.
More information about the unit and its full service portfolio is available on the NANBIOSIS website.

https://www.youtube.com/shorts/PwYuCOJALlE

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Open Call page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them: